Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
2.050
-0.050 (-2.38%)
Sep 3, 2026, 4:00 PM EDT - Market closed

Processa Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-12.86-13.99-12.05-11.46-20.26-11.57
Net Income
-13.44-13.56-11.85-11.12-27.42-11.43
Earnings Per Share
-5.59-10.36-96.78-211.99-851.18-372.97
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
0.25.541.194.716.516.5
Total Debt
--0.070.150.230.08
Net Cash (Debt)
0.25.541.124.566.2716.42
Net Cash Growth
-97.16%395.34%-75.46%-27.39%-61.79%8.82%
Net Cash Per Share
0.084.239.1386.84194.73535.89

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-11.97-11.39-11.25-8.06-9.61-8.72
Capital Expenditures
---0-0--
Free Cash Flow
-11.97-11.39-11.25-8.07-9.61-8.72
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.